Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Regorafenib and Nivolumab in Recurrent or Metastatic Solid Tumors
2020-003359-13Phase 2Unknown
- Sponsor
- Bayer
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and nivolumab in Non-hematologic malignancy, sponsored by Bayer. Primary endpoint: Overall response rate. Status: unknown.
02
Drugs
regorafenibnivolumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2020-003359-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003359-13.